| 书目名称 | Integration of Pharmaceutical Discovery and Development | | 副标题 | Case Histories | | 编辑 | Ronald T. Borchardt,Roger M. Freidinger,Philip L. | | 视频video | | | 丛书名称 | Pharmaceutical Biotechnology | | 图书封面 |  | | 描述 | In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinet | | 出版日期 | Book 1998 | | 关键词 | Nucleoside; chemistry; development; metabolism; pharmaceutical; receptor | | 版次 | 1 | | doi | https://doi.org/10.1007/b114429 | | isbn_softcover | 978-1-4419-3288-4 | | isbn_ebook | 978-0-306-47384-5Series ISSN 1078-0467 | | issn_series | 1078-0467 | | copyright | Springer Science+Business Media New York 1998 |
The information of publication is updating
|
|
发表于 2025-3-21 18:21:32
